(Q43889892)

English

Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients

scientific article published in February 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Teruo Inoue

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Masatoshi Hayashi

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Kan Takayanagi

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Shigenori Morooka

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 February 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

160

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

369-376

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Role of oxidized low density lipoprotein in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Modified forms of low density lipoprotein and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Superoxide anion scavenging properties of fluvastatin and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Mechanism of antioxidative activity of fluvastatin-determination of the active position

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Hydroxymethylglutaryl coenzyme a reductase inhibition: fluvastatin, a clinical investigators' update. Introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Autoantibody against oxidised LDL and progression of carotid atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Low-density lipoprotein oxidation in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Antibody against oxidized low-density lipoprotein predicting myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Hypercholesterolemia increases endothelial superoxide anion production

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900585-8

7 January 2021

Identifiers

10.1016/S0021-9150(01)00585-8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43889892&oldid=2104177213"